Completely understanding LOX-1 and its splice variant Δ4 molecular pathways in breast cancer molecular phenotypes could represent a new challenge for targeting tumor metabolic pathway involved in proliferation, drug resistance acquisition and to improve a tailored therapy to individual subtypes. Here, OLR1 is linked to breast cancer.